Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice
详细信息 查看全文
- 作者：Atsuko Okamoto ; Takashi Nojiri ; Kazuhisa Konishi ; Takeshi Tokudome…
- 关键词：Atrial natriuretic peptide ; Pulmonary fibrosis ; Bleomycin ; Vascular endothelial cell ; Transforming growth factor ; β
- 刊名：Respiratory Research
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：18
- 期：1
- 全文大小：1221KB
- 刊物主题：Pneumology/Respiratory System;
- 出版者：BioMed Central
- ISSN：1465-993X
- 卷排序：18
文摘
BackgroundPulmonary fibrosis is a life-threatening disease characterized by progressive dyspnea and worsening pulmonary function. Atrial natriuretic peptide (ANP), a heart-derived secretory peptide used clinically in Japan for the treatment of acute heart failure, exerts a wide range of protective effects on various organs, including the heart, blood vessels, kidneys, and lungs. Its therapeutic properties are characterized by anti-inflammatory and anti-fibrotic activities mediated by the guanylyl cyclase-A (GC-A) receptor. We hypothesized that ANP would have anti-fibrotic and anti-inflammatory effects on bleomycin (BLM)-induced pulmonary fibrosis in mice.